Literature DB >> 20717691

Occupational asthma caused by triglycidyl isocyanurate.

Joaquín Sastre1, Jerónimo Carnes, Manuela García del Potro, Luis Manso, Erika Aguado, Mar Fernández-Nieto.   

Abstract

BACKGROUND: Several cases of allergic contact dermatitis, two cases of occupational asthma from over one decade ago and one case of hypersensitivity pneumonitis have been documented in painters who use polyester powder paint containing triglycidyl isocyanurate (TGIC).
METHODS: We report a 28-year-old female who, 4 months after beginning work in a powder-coating factory, developed asthma-like symptoms. In her workplace, aluminium frames were treated with an electrostatic powder paint containing 2.5-10% TGIC.
RESULTS: Serial peak-flow measurements performed during both working and non-working periods demonstrated peak-flow variability of up to 46% on work days. Bronchial methacholine test results also varied between times at work and away from work. PC(20) methacholine was 0.32 mg/ml and fraction of exhaled nitric oxide (FENO) was 18 ppb. A controlled exposure challenge was performed with a placebo yielding no changes in FEV(1) over a 24-hour period. On visit 2, the patient was placed in the chamber and exposed to TGIC (4% in lactose) at a mean concentration of 3.61 mg/m(3) for a total of 15 min. A 20% fall in FEV(1) from baseline was elicited at 10 min, together with cough and wheezing. No late response was demonstrated. Twenty-four hours after the challenge, neither methacholine PC(20) nor FENO levels varied from baseline values. No IgE was detected by ELISA testing and no IgE-binding bands were found by immunoblot analysis of patient and control serum.
CONCLUSIONS: The aforementioned results demonstrate that TGIC inhalation induced immunologic occupational asthma, although no IgE mechanism was evidenced.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717691     DOI: 10.1007/s00420-010-0570-y

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  8 in total

1.  Sensitization to triglycidylisocyanurate (TGIC) with cutaneous and respiratory manifestations.

Authors:  L Meuleman; A Goossens; C Linders; F Rochette; B Nemery
Journal:  Allergy       Date:  1999-07       Impact factor: 13.146

2.  Hypersensitivity pneumonitis caused by triglycidyl isocyanurate.

Authors:  S Quirce; M Fernàndez-Nieto; M Górgolas; G Renedo; J Carnés; J Sastre
Journal:  Allergy       Date:  2004-10       Impact factor: 13.146

3.  Contact dermatitis caused by triglycidyl isocyanurate.

Authors:  W Wigger-Alberti; M Hofmann; P Elsner
Journal:  Am J Contact Dermat       Date:  1997-06

4.  Need for monitoring nonspecific bronchial hyperresponsiveness before and after isocyanate inhalation challenge.

Authors:  Joaquín Sastre; Mar Fernández-Nieto; Ana Novalbos; Manuel De Las Heras; Javier Cuesta; Santiago Quirce
Journal:  Chest       Date:  2003-04       Impact factor: 9.410

5.  Occupational asthma caused by triglycidyl isocyanurate (TGIC).

Authors:  P Piirilä; T Estlander; H Keskinen; R Jolanki; A Laakkonen; P Pfäffli; O Tupasela; M Tuppurainen; H Nordman
Journal:  Clin Exp Allergy       Date:  1997-05       Impact factor: 5.018

6.  Respiratory and systemic reaction following exposure to heated electrostatic polyester paint.

Authors:  A Cartier; O Vandenplas; L C Grammer; M A Shaughnessy; J L Malo
Journal:  Eur Respir J       Date:  1994-03       Impact factor: 16.671

7.  Allergic alveolitis following exposure to epoxy polyester powder paint containing low amounts (<1%) of acid anhydrides.

Authors:  P Piirilä; H Keskinen; S Anttila; M Hyvönen; P Pfäffli; T Tuomi; O Tupasela; M Tuppurainen; H Nordman
Journal:  Eur Respir J       Date:  1997-04       Impact factor: 16.671

8.  Changes in sputum eicosanoids and inflammatory markers after inhalation challenges with occupational agents.

Authors:  Mar Fernández-Nieto; Beatriz Sastre; Joaquín Sastre; Carlos Lahoz; Santiago Quirce; Mauro Madero; Victoria Del Pozo
Journal:  Chest       Date:  2009-06-08       Impact factor: 9.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.